about
Dopamine beta-hydroxylase deficiencyCharacterization and distribution of alpha 2-adrenergic receptors in the human intestinal mucosaAdult resident cardiomyocytes wake up: new axis for cardiac tissue regenerationA study of tolerance to apomorphineAdrenomedullin inhibits adipogenesis under transcriptional control of insulinCardiac transcriptome analysis in obesity-related hypertension.Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France.[Ambulatory measurement of blood pressure and plasma catecholamines in the study of orthostatic hypotension]A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.Effects of physiological and pharmacological variation of sympathetic nervous system activity on plasma non-esterified fatty acid concentrations in man[Biological factors of PTSD: neurotransmitters and neuromodulators]Differential β₂-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell linesEffects of yohimbine, an alpha 2-adrenoceptor antagonist, on experimental neurogenic orthostatic hypotension.Adrenomedullin upregulates M2-muscarinic receptors in cardiomyocytes from P19 cell lineAcute electromyostimulation decreases muscle sympathetic nerve activity in patients with advanced chronic heart failure (EMSICA Study)Direct evidences for sympathetic hyperactivity and baroreflex impairment in Tako Tsubo cardiopathy.Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signalingPharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management.Myocardial hypertrophy, cardiac beta-adrenoceptors and adenylate cyclase activity during sinoaortic denervation in dogs.Cardiac fibroblasts regulate sympathetic nerve sprouting and neurocardiac synapse stabilityNeurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?Probing heterotrimeric G protein activation: applications to biased ligands.Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.Uncomplicated human obesity is associated with a specific cardiac transcriptome: involvement of the Wnt pathway.Biophysical properties of cardiomyocyte surface explored by multiparametric AFM.Delineating biased ligand efficacy at 7TM receptors from an experimental perspective.Exercise training-induced modification in autonomic nervous system: An update for cardiac patients.Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals.Cardioprotective Angiotensin-(1-7) Peptide Acts as a Natural-Biased Ligand at the Angiotensin II Type 1 Receptor.Deciphering biased-agonism complexity reveals a new active AT1 receptor entity.Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group.Drug-induced parkinsonism: a review.Adrenoceptor regulation in orthostatic hypotension during autonomic failure.Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects.Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences.New directions in the drug treatment of Parkinson's disease.The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD studyG protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning.Identification of human platelet alpha 2-adrenoceptors with a new antagonist [3H]-RX821002, a 2-methoxy derivative of idazoxan.
P50
Q21093171-9CDDCB43-986B-4A88-B53D-42413411EE78Q24598150-9DDF36AF-C9E7-4E76-A8AC-2CF2614F734DQ27011238-25340D93-C258-4938-A356-8DC3E646B10BQ28379212-5716CBE6-B7CA-434B-8959-04EADC15DFE0Q28583236-C7B89F24-DFFA-4BE8-8648-F07C91BC0C58Q30892751-5C5176F4-717C-4F7E-B7DF-4972E43C5DCDQ33152867-0CDBC629-608B-4FC2-A0EF-4AA793A3DA6EQ33173780-B398F180-931E-48D4-97B5-AA212C0E71CFQ33733049-B2200A70-1153-41D0-B8D6-752C153D5063Q34324746-EA343313-0AA8-49F2-AD52-C35636DBCAD1Q34345445-77B333F2-7D1F-4DBB-9A92-5548280E403CQ34524818-69D4E3F2-9EB8-44AF-A3FE-3081989F790CQ34654398-364009F7-A169-43D3-B2AD-3A058412BEB1Q34744770-535DB137-3869-4829-B174-A2E36C5747F3Q35045528-02F6B0EB-62B3-46F1-BF03-F03768A30A20Q35050477-8175B746-C43B-4719-A1E0-837DE56F2F07Q35131097-733B0838-83BA-4EB0-BF7A-6D4E814B424CQ35738220-811936FA-D208-4A70-9DC8-FB381E8AFFB7Q35777401-14AE2509-896E-4060-9369-11E79A299FD1Q35872400-AF63BE15-97E1-4A3B-AEE6-409EA082D345Q37309358-40F059A8-0687-43F4-A06A-03F2BFE9BE6DQ37785327-794F6F43-FD25-47F9-AEEF-3965B8E89BE7Q37974268-13CE20B8-2311-4E13-87D6-73FDBDC0128EQ38099679-BEA405CA-3867-4C5B-8334-94C715A203F0Q38521722-1D315AF9-A17F-4716-847F-1F56A3EBBBD1Q38750062-5AD24A26-A9BE-47BE-816B-B69878C85D75Q38815819-6C55343A-01A1-4E7E-8F4B-BC149BDD06E6Q38932096-90AB4D32-482D-4A4C-BBB6-C517CA6AEEF0Q39048230-1C12CC9D-D6C3-4A25-B519-DD37FD2F640DQ39326902-932889FD-0E79-42E3-8787-0A0383B273FDQ39341454-CF09B2C8-C667-4ED8-B728-E8BE6A26546EQ39461265-9F6D886A-22AE-4CE0-97DA-2788155D6E9DQ40590287-638E4FB4-7CA1-472E-92A6-AF8B9B1EF23FQ40808669-2914C2EA-90A3-4FB8-AD97-71DA1374AC73Q40824062-8C159CB4-18EF-4705-8E50-FA159556F69BQ40978699-5E0318D2-9B14-4BE3-B663-C11F14CB4291Q41172471-CE4D2C5B-BF26-4B36-8F3A-9482FC632B8BQ41363544-7DC2B71E-8C63-4AB2-83B6-CAEFD18D633CQ41367745-88F5B174-021A-46FF-B8B3-3102EAF4FA22Q41952560-CB72E225-3B6F-4D4A-BB40-5BFFD3C54FBB
P50
description
farmacoloog
@nl
researcher ORCID ID = 0000-0001-7679-1281
@en
name
Jean-Michel Sénard
@ast
Jean-Michel Sénard
@en
Jean-Michel Sénard
@es
Jean-Michel Sénard
@fr
Jean-Michel Sénard
@nl
type
label
Jean-Michel Sénard
@ast
Jean-Michel Sénard
@en
Jean-Michel Sénard
@es
Jean-Michel Sénard
@fr
Jean-Michel Sénard
@nl
altLabel
J M Senard
@en
Jean-Michel Senard
@en
prefLabel
Jean-Michel Sénard
@ast
Jean-Michel Sénard
@en
Jean-Michel Sénard
@es
Jean-Michel Sénard
@fr
Jean-Michel Sénard
@nl
P214
P269
P21
P214
P269
P31
P496
0000-0001-7679-1281
P735
P7859
viaf-172551000